The cancer drug manufacturing companies in Nan industry focuses on producing medications designed for cancer treatment. These companies range from established pharmaceutical giants to innovative startups that emphasize research and development. They produce a variety of products, including chemotherapy and immunotherapy drugs, targeting various cancer types with advanced formulations. The industry is evolving rapidly, driven by increasing investment in biotechnology and personalized medicine, which aim to provide more effective and tailored treatment options. As the global demand for cancer therapies continues to rise, this sector is poised for significant growth and technological advancements.


This list features 26 notable cancer drug manufacturers headquartered in locations such as India, the USA, and China. Ranging in size from small firms to large corporations, these companies were established between the early 1990s and 2022. Their primary focus includes developing oncology medicines and therapies, showcasing remarkable innovations to combat cancer. Each company plays an important role, tailoring its efforts to meet the evolving needs of patients and healthcare providers worldwide.


Continue reading to explore top cancer drug manufacturing companies.


Top 26 Cancer Drug Manufacturing Companies


1. TherDose Pharma Private Limited


TherDose Pharma Private Limited, based in Hyderabad, Telangana, India, is a private pharmaceutical company founded in 2003. The company specializes in the development and manufacturing of oncology medicines, particularly chemotherapy drugs. With a dedicated in-house research and development team, TherDose aims to enhance patient outcomes by providing innovative and affordable cancer treatment options. Over the years, they have developed more than 35 generics and specialty drugs, filing 40 dossiers across 25 countries in emerging markets. Their manufacturing capabilities include a range of dosage forms, such as tablets, capsules, and injectables, all designed to meet stringent quality standards. TherDose is committed to expanding its global presence and achieving regulatory compliance, with aspirations to increase product registrations worldwide.


2. Chi-Med (Hutchison China MediTech)

  • Website: chi-med.com
  • Ownership type: Private
  • Headquarters: Hong Kong S.A.R
  • Founded year: 2000
  • Headcount: 5001-10000
  • LinkedIn: hchimed

Chi-Med (Hutchison China MediTech) is a biopharmaceutical company based in Hong Kong, founded in 2000. The company specializes in the discovery, development, and commercialization of targeted therapies and immunotherapies aimed at treating cancer and autoimmune diseases. Chi-Med has a robust pipeline of drug candidates, with several in clinical development stages. Notably, their drug surufatinib has received orphan drug designation from the FDA for the treatment of pancreatic neuroendocrine tumors, indicating its potential to meet significant medical needs. The company operates with a dedicated research team and has established a commercial platform for marketing its products in China, making it a significant player in the biopharmaceutical industry.


3. Taiho Oncology, Inc.

  • Website: taihooncology.com
  • Ownership type: Private
  • Headquarters: United States (USA)
  • Employee distribution: United States (USA) 96%, Canada 2%, Other 2%
  • Founded year: 2002
  • Headcount: 201-500
  • LinkedIn: taiho-oncology-inc

Taiho Oncology, Inc. is a pharmaceutical company based in Princeton, New Jersey, established in 2002. It specializes in the development and commercialization of innovative anti-cancer therapies, focusing on effective treatments for patients with various types of cancer, including solid tumors and hematological malignancies. The company operates with a strong emphasis on research and development, aiming to improve patient outcomes in oncology. Taiho Oncology has successfully brought several products to market, including LONSURF (trifluridine and tipiracil), INQOVI (decitabine and cedazuridine), and LYTGOBI (futibatinib), all of which have received FDA approval. The company is a subsidiary of Taiho Pharmaceutical Co., Ltd., which is part of Otsuka Holdings Co., Ltd., providing it with substantial resources and capabilities to advance its mission. Taiho Oncology is actively involved in clinical trials and has a pipeline of investigational agents, reflecting its commitment to innovation in cancer treatment.


4. Haihe Biopharma

  • Website: haihepharma.com
  • Ownership type: Private Equity
  • Headquarters: Shanghai, Shanghai, China
  • Employee distribution: China 90%, Japan 10%
  • Latest funding: Series B, $171.0M, July 2020
  • Founded year: 2011
  • Headcount: 51-200
  • LinkedIn: haihe-biopharma

Haihe Biopharma Co., Ltd. is a Shanghai-based biopharmaceutical company founded in 2011. The company is dedicated to the discovery, development, production, and commercialization of innovative anti-tumor drugs. With a strong emphasis on oncology, Haihe Biopharma has developed products like Gumarontinib, an oral MET inhibitor that has been conditionally approved by the National Medical Products Administration (NMPA) in China. The company operates globally, with research and development centers in the United States and Japan, and aims to provide life-saving therapies to cancer patients worldwide. Haihe Biopharma has also secured significant funding, including a Series B round that raised approximately 1.2 billion yuan in 2020, which supports their ongoing research and development efforts. Their pipeline includes over ten oncology and non-oncology compounds, indicating a commitment to addressing unmet medical needs in cancer treatment.


5. Beta Pharma, Inc.

  • Website: betapharma.com
  • Ownership type: Private
  • Headquarters: United States (USA)
  • Employee distribution: China 39%, United States (USA) 39%, Egypt 11%, Other 11%
  • Founded year: 1996
  • Headcount: 11-50
  • LinkedIn: beta-pharma-inc-

Beta Pharma, Inc. is a private pharmaceutical company based in the United States, founded in 1996. Initially established as a contract research organization, it has since evolved into a dedicated entity for oncology research and drug development. The company specializes in creating innovative therapies aimed at improving the quality of life for cancer patients. Their product pipeline includes several notable candidates, such as BPI-2009H (Icotinib), a first-generation EGFR-TKI, and BPI-7711 (Rezivertinib), a third-generation EGFR-TKI. Beta Pharma has successfully marketed icotinib in China, capturing a significant market share in lung cancer therapies. The company actively collaborates with healthcare professionals and pharmaceutical partners to enhance the accessibility of their treatments. With a focus on late-stage therapies, Beta Pharma is committed to advancing cancer care through rigorous research and development efforts.


6. Sobhan Oncology Pharmaceutical


Sobhan Oncology Pharmaceutical, established in 2002 and located in Rasht, Gilan, Iran, is a private company dedicated to the production of oncology medications. It is recognized as one of the most advanced facilities for manufacturing anti-cancer drugs in the Middle East. The company emphasizes high-quality production standards and has implemented international quality guidelines, including those from the FDA and PIC/S. Sobhan Oncology collaborates with reputable global pharmaceutical companies such as Roche, Sanofi, and Cipla, which allows it to produce a range of oncology products under license. The company is committed to addressing the needs of cancer patients by providing innovative solutions and ensuring the availability of essential treatments at reasonable prices. Sobhan Oncology also engages in exporting its products to various countries, further solidifying its presence in the international market.


7. Radiomedix, Inc.

  • Website: radiomedix.com
  • Ownership type: Private Equity
  • Headquarters: Houston, Texas, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: Series A, $40.0M, October 2022
  • Founded year: 2006
  • Headcount: 11-50
  • LinkedIn: radiomedix-inc-

Radiomedix, Inc. is a clinical-stage biotechnology firm based in Houston, Texas, founded in 2006. The company is dedicated to developing innovative targeted radiopharmaceuticals aimed at improving cancer diagnosis and therapy. Radiomedix operates across the entire spectrum of drug development, from initial discovery through to commercial-scale manufacturing. They provide a range of services, including drug formulation optimization, preclinical studies, and compliance with regulatory standards for clinical trials. Their capabilities extend to the production of radiopharmaceuticals for PET imaging and targeted therapies, which are essential for precise cancer treatment. Recently, Radiomedix secured $40 million in Series A funding, reflecting strong investor confidence in their mission to enhance patient outcomes through advanced nuclear medicine solutions.


8. Ciro Pharma Private Limited

  • Website: ciropharmagroup.com
  • Ownership type: Private
  • Headquarters: Hyderabad, Telangana, India
  • Employee distribution: India 100%
  • Founded year: 2022
  • Headcount: 201-500
  • LinkedIn: ciropharmagroup

Ciro Pharma Private Limited, based in Hyderabad, Telangana, India, is a pharmaceutical manufacturer that focuses on the production of anti-cancer drugs and dietary supplements. Founded in 2022, the company is currently establishing a modern manufacturing facility at Biotech Park Phase III. This facility is designed to meet regulatory standards for various international markets, including the USA, UK, Europe, Canada, and South America. Ciro Pharma's product portfolio includes monoclonal antibodies and cancer therapeutics available in oral solid dosages, capsules, and injectables. Additionally, they are developing nutritional supplements in soft gel capsule form specifically for cancer patients. The company emphasizes quality assurance and aims to provide affordable health solutions, reflecting a commitment to improving patient care in oncology. Their R&D efforts are geared towards addressing specific challenges faced by cancer patients, such as renal failures and malnutrition, indicating a proactive approach to product development in the oncology sector.


9. Florencia HealthCare


Florencia HealthCare, established in 2011 and based in Noida, Uttar Pradesh, India, is a private pharmaceutical manufacturer with a workforce of around 21 employees. The company specializes in the production of oncology medicines, antibiotics, and biologicals. Florencia is committed to making high-quality, affordable medications accessible to patients and healthcare providers. Their product portfolio includes various anticancer formulations such as liquid injections, lyophilized injections, tablets, and capsules. The company operates under stringent quality control measures and adheres to WHO-cGMP guidelines, ensuring that their products meet international standards. Florencia's focus on research and development is evident in their continuous efforts to innovate and improve treatment options for patients suffering from life-threatening diseases. They have expanded their reach to over 15 countries, providing more than 500 approved products, and are actively involved in enhancing healthcare accessibility globally.


10. Getwell Oncology

  • Website: getwelloncology.com
  • Ownership type: Family Owned
  • Headquarters: Gurugram, Haryana, India
  • Employee distribution: India 98%, Ghana 2%
  • Founded year: 1985
  • Headcount: 51-200
  • LinkedIn: getwell-oncology

Getwell Oncology, based in Gurugram, Haryana, India, is a family-owned pharmaceutical company that has been dedicated to the manufacture of high-quality oncology drugs since its inception in 1985. With a workforce of approximately 93 employees, the company specializes in producing sterile oncology dosage forms, including liquid vials and lyophilized vials. Getwell's products are designed to meet the needs of healthcare providers and hospitals, ensuring effective treatment options for cancer patients. The company operates in more than 20 countries, demonstrating its commitment to improving cancer care through advanced drug formulations. Getwell Oncology emphasizes quality and innovation, with a robust research and development framework that supports the creation of complex generics and drug delivery systems. Their focus on patient well-being and collaboration with healthcare institutions further underscores their role in the oncology sector.


11. Eurolab (Pty) Ltd.

  • Website: eurolab.co.za
  • Ownership type: Private
  • Headquarters: Sandton, Gauteng, South Africa
  • Employee distribution: South Africa 100%
  • Founded year: 2011
  • Headcount: 11-50
  • LinkedIn: eurolab-pty-ltd

Eurolab (Pty) Ltd., founded in 2011 and based in Sandton, Gauteng, South Africa, is a private healthcare and pharmaceutical company that specializes in oncology. With a workforce of approximately 43 employees, Eurolab has established itself as South Africa's largest generic oncology company. The firm offers a comprehensive range of products and services, including generic oncology medicines and chemotherapy products, aimed at enhancing cancer treatment accessibility and outcomes. Their innovative initiatives include the Aseptic Services Unit, which provides sterile manufacturing services, and Oncolab, a specialized testing facility for oncology and haematology diagnostics. Eurolab's commitment to improving patient care is evident in their partnerships and the introduction of advanced technologies, such as the Gamma Knife for non-invasive radiosurgery. Their focus on affordability and quality in cancer treatment positions them as a significant player in the South African oncology market.


12. Innokeys Pte Ltd

  • Website: innokeys.com
  • Ownership type: Private
  • Headquarters: Singapore
  • Employee distribution: Indonesia 59%, Singapore 41%
  • Founded year: 2012
  • Headcount: 11-50
  • LinkedIn: innokeys-pte-ltd

Innokeys Pte Ltd is a Singapore-based biotechnology firm founded in 2012. The company is dedicated to developing and commercializing innovative biopharmaceuticals, with a strong emphasis on oncology. Innokeys is known for its product nimotuzumab, a recombinant monoclonal antibody targeting the epidermal growth factor receptor (EGFR), which plays a crucial role in the proliferation of cancer cells. Nimotuzumab is utilized in treating various solid tumors, including head and neck cancer, pancreatic cancer, and gastric cancer, and has received approval in more than 30 countries. The company collaborates with international partners to coordinate global development activities for nimotuzumab, demonstrating its active engagement in the oncology sector. Innokeys aims to fulfill unmet medical needs through its innovative solutions in biopharmaceuticals, making significant contributions to cancer treatment options.


13. ImmuneOncia Therapeutics Inc.

  • Website: immuneoncia.com
  • Ownership type: Venture Capital
  • Headquarters: Gangseo-Gu, Seoul, South Korea
  • Employee distribution: South Korea 100%
  • Latest funding: $20.6M, January 2022
  • Founded year: 2016
  • Headcount: 11-50
  • LinkedIn: immuneoncia

ImmuneOncia Therapeutics Inc. is a biopharmaceutical company based in Gangseo-Gu, Seoul, South Korea, founded in 2016. The company specializes in immuno-oncology, focusing on the development of innovative immunotherapies, particularly monoclonal antibodies that target cancer. ImmuneOncia aims to improve the lives of oncology patients worldwide by leveraging advanced drug development techniques. Their current pipeline includes IMC-001, an anti-PD-L1 monoclonal antibody, which has received approval for a multi-regional Phase II study in Korea and China, and IMC-002, an anti-CD47 monoclonal antibody, which has initiated a Phase I study in the U.S. The company operates as a joint venture between Yuhan Corporation and Sorrento Therapeutics, combining expertise in drug development and antibody engineering. Recently, ImmuneOncia secured funding of approximately $20.6 million, further supporting their research initiatives.


14. Sudair Pharmaceutical Company

  • Website: sudairpharma.com
  • Ownership type: Corporate
  • Headquarters: Riyadh, Riyadh, Saudi Arabia
  • Employee distribution: Saudi Arabia 100%
  • Latest funding: November 2021
  • Founded year: 2014
  • Headcount: 51-200
  • LinkedIn: sudairpharma

Sudair Pharmaceutical Company, established in 2014 and based in Riyadh, Saudi Arabia, is a pharmaceutical manufacturer that specializes in oncology medications and other specialized treatments. The company aims to meet the medical needs of healthcare providers and patients by producing high-quality pharmaceuticals locally. Sudair Pharma has developed a robust portfolio that addresses more than nine types of tumors, including targeted therapies and classic chemotherapy. Recently, they inaugurated a dedicated oncology manufacturing site for injections, further solidifying their role in cancer treatment. The company is committed to enhancing access to essential medications and has been actively involved in localizing drug production to improve healthcare outcomes in the region.


15. Dendreon

  • Website: dendreon.com
  • Ownership type: Corporate
  • Headquarters: Seal Beach, California, United States (USA)
  • Employee distribution: United States (USA) 97%, Other 3%
  • Latest funding: $819.9M, June 2017
  • Founded year: 1992
  • Headcount: 501-1000
  • LinkedIn: dendreon

Dendreon Pharmaceuticals LLC, founded in 1992 and based in Seal Beach, California, is a biotechnology company that focuses on immunotherapy for cancer treatment. Its flagship product, Provenge (sipuleucel-T), is the first FDA-approved cellular immunotherapy for advanced prostate cancer, utilizing the patient's own immune cells to enhance the body's ability to fight cancer. Since its approval in 2010, Provenge has been prescribed to nearly 40,000 men, demonstrating its impact on patient outcomes. In addition to its therapeutic offerings, Dendreon provides cellular therapy manufacturing services, assisting other companies in the development and commercialization of innovative cancer therapies. The company has a robust infrastructure that supports clinical research and manufacturing, positioning it as a key player in the cancer treatment landscape. Dendreon continues to invest in research and clinical trials to explore the potential of Provenge in various patient populations, further solidifying its commitment to improving cancer care.


16. Nano Daru

  • Website: nanodaru.com
  • Ownership type: Private
  • Headquarters: Tehran, Tehran, Iran
  • Employee distribution: Iran 100%
  • Founded year: 2011
  • Headcount: 201-500
  • LinkedIn: nano-daru

Nano Daru, founded in 2011 and based in Tehran, Iran, is a private pharmaceutical company dedicated to the development of innovative drug delivery systems and oncology products. With a workforce of approximately 83 employees, the company has made significant strides in the pharmaceutical industry, particularly in cancer treatment. They have successfully launched products like Paclinab, a solvent-free colloidal suspension of paclitaxel, which aims to reduce the toxicities associated with conventional therapies. Their product line also includes Palbociclib and Pralatrexate, both of which target specific cancer types. Nano Daru emphasizes scientific innovation and ethical practices, striving to improve patient outcomes through high-quality medications. Their commitment to research and development in oncology showcases their active involvement in addressing cancer treatment challenges.


17. 1200 Pharma

  • Website: 1200pharma.com
  • Ownership type: Venture Capital
  • Headquarters: Culver City, California, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: $2.3M, April 2024
  • Founded year: 2017
  • Headcount: 11-50
  • LinkedIn: 1200-pharma

1200 Pharma is a pharmaceutical and biotechnology company based in Culver City, California, established in 2017. The firm specializes in drug discovery and development, particularly targeting oncology. With a team of experienced professionals from prestigious institutions like Caltech and UCLA, 1200 Pharma employs advanced medicinal chemistry and data-driven research methodologies to develop innovative cancer therapies. Their approach includes leveraging proprietary genomic and protein expression datasets from over 500 human cancer cell lines to identify therapeutic targets. The company is actively engaged in clinical trials, with several candidates in various stages of development, including Phase 1 trials for specific cancer indications. In April 2024, 1200 Pharma secured $2,325,500 in funding, reflecting investor confidence in their research and development capabilities. Their collaborations with clinical research organizations further facilitate the translation of their findings into effective treatments for patients.


18. Kite Pharma

  • Website: kitepharma.com
  • Ownership type: Corporate
  • Headquarters: Santa Monica, California, United States (USA)
  • Employee distribution: United States (USA) 65%, Netherlands 28%, United Kingdom (UK) 2%, Other 5%
  • Latest funding: $11.9B, August 2017
  • Founded year: 2009
  • Headcount: 1001-5000
  • LinkedIn: kite-pharma-inc-

Kite Pharma, Inc., founded in 2009 and based in Santa Monica, California, is a biotechnology company dedicated to developing innovative cancer immunotherapy products. The company specializes in CAR T-cell therapies, which utilize the patient's own immune system to target and attack cancer cells. Kite Pharma has made significant strides in treating various blood cancers, with a strong emphasis on research and development to ensure access to advanced therapies. Their notable products include YESCARTA (axicabtagene ciloleucel) and TECARTUS (brexucabtagene autoleucel), which have been pivotal in changing treatment paradigms for patients with hematological malignancies. Kite operates a global manufacturing network and collaborates with numerous treatment centers to facilitate patient access to their therapies. The company is a subsidiary of Gilead Sciences, which has further bolstered its capabilities and resources in the field of cancer treatment.


19. Anaveon Ag

  • Website: anaveon.com
  • Ownership type: Venture Capital
  • Headquarters: Basel, Basel, Switzerland
  • Employee distribution: Switzerland 89%, France 11%
  • Latest funding: Series B, $119.7M, December 2021
  • Founded year: 2017
  • Headcount: 11-50
  • LinkedIn: anaveon-ag

Anaveon Ag, based in Basel, Switzerland, is a biotechnology firm founded in 2017. The company specializes in the development of engineered cytokines aimed at cancer immunotherapy. Anaveon is dedicated to creating innovative treatments that enhance immune responses against tumors, targeting healthcare professionals and researchers in the pharmaceutical industry. Their clinical pipeline includes promising candidates such as ANV419, an IL-2/anti-IL-2 antibody fusion protein, and ANV600, which is designed to work in combination with existing therapies like PD-1 inhibitors. Anaveon has successfully raised over CHF 146 million since its inception, with the latest funding round in December 2021 amounting to CHF 119 million. This financial backing supports their ongoing research and development efforts, positioning them as a significant entity in the oncology sector.


20. Xuanzhu Biopharmaceutical Co., Ltd.

  • Website: xuanzhubio.com
  • Ownership type: Private
  • Headquarters: Shijiazhuang, Hebei, China
  • Founded year: 2002
  • Headcount: 201-500
  • LinkedIn: xuanzhupharm

Xuanzhu Biopharmaceutical Co., Ltd., founded in 2002 and based in Shijiazhuang, Hebei, China, is a private biopharmaceutical company dedicated to the research, development, and commercialization of innovative drugs. The company specializes in oncology and NASH (Non-Alcoholic Steatohepatitis), aiming to meet significant medical needs through advanced therapeutic solutions. Xuanzhu has developed a comprehensive drug research and development system, covering everything from initial project evaluation to clinical trials and commercialization. They have a strong focus on cancer, particularly breast cancer and non-small cell lung cancer, with over 30 products in their research pipeline. The company has also been recognized for its innovative capabilities, receiving accolades such as being listed among China’s unicorn enterprises. Their commitment to drug safety and efficacy is evident in their extensive clinical trials and regulatory submissions, including recent applications for new drug approvals.


21. Peptomyc

  • Website: peptomyc.com
  • Ownership type: Venture Capital
  • Headquarters: Barcelona, Catalonia, Spain
  • Employee distribution: Spain 100%
  • Latest funding: $3.3M, January 2022
  • Founded year: 2014
  • Headcount: 11-50
  • LinkedIn: peptomyc

Peptomyc is a biotechnology company based in Barcelona, Spain, founded in 2014. The company specializes in developing innovative cancer treatments, particularly through the use of MYC inhibitors. Their primary product, OMO-103, is a mini-protein therapeutic designed to directly inhibit MYC, which plays a significant role in cancer cell proliferation and survival. Peptomyc emerged as a spin-off from the Vall d’Hebron Institute of Oncology (VHIO) and has a team of experts, including its co-founders Dr. Laura Soucek and Dr. Marie-Eve Beaulieu, who have extensive backgrounds in oncology and protein science. The company has made strides in its clinical development, having completed a Phase I study that demonstrated the safety and clinical activity of OMO-103 in solid tumor patients. In addition, Peptomyc has secured funding, including a recent amount of over €4 million from the Spanish Ministry of Science and Innovation, to further advance its clinical programs. Peptomyc aims to improve patient outcomes and quality of life for cancer patients through its pioneering approach to MYC inhibition.


22. Pinnacle Life Science Pvt. Ltd (Subsidiary of Aarti Drugs)


Pinnacle Life Science Pvt. Ltd, a subsidiary of Aarti Drugs, was founded in 2014 and is based in Mumbai, Maharashtra, India. The company specializes in the formulation and export of innovative pharmaceutical solutions, with a strong emphasis on oncology, cardiovascular health, and anti-infective treatments. Pinnacle operates state-of-the-art manufacturing facilities that have received multiple regulatory approvals, including from the US FDA. They produce billions of tablets and capsules annually, with a significant portion dedicated to oncology products. Their commitment to quality and safety is reflected in their adherence to global regulatory standards, making them a reliable partner for healthcare providers and pharmaceutical companies worldwide. Pinnacle's R&D efforts focus on developing new formulations and improving existing ones, ensuring they remain competitive in the pharmaceutical market.


23. Tallac Therapeutics

  • Website: tallactherapeutics.com
  • Ownership type: Venture Capital
  • Headquarters: Burlingame, California, United States (USA)
  • Employee distribution: United States (USA) 100%
  • Latest funding: Other (Debt), $5.0M, August 2023
  • Founded year: 2018
  • Headcount: 11-50
  • LinkedIn: tallac-therapeutics

Tallac Therapeutics is a clinical-stage biopharmaceutical company based in Burlingame, California, founded in 2018. The company specializes in creating innovative cancer therapies, particularly through the use of antibody drug conjugates (ADCs) and immunotherapy. Their pipeline includes a range of oligonucleotide-based ADC candidates, notably their Toll-like Receptor Agonist Antibody Conjugates (TRAAC), which are designed to deliver potent immune activators directly to tumors. Tallac's approach is centered on enhancing the immune response within the tumor microenvironment, aiming to improve treatment outcomes for cancer patients. The company has recently secured $5 million in funding, indicating ongoing investor interest and support for their development efforts. With several programs in clinical trials, Tallac Therapeutics is positioned to make significant contributions to the field of oncology.


24. MSD Sharp & Dohme GmbH

  • Website: msd.de
  • Ownership type: Private
  • Headquarters: Amt Neuhaus, Lower Saxony, Germany
  • Founded year: 2001
  • Headcount: 1001-5000
  • LinkedIn: msd-sharp-%26-dohme-gmbh

MSD Sharp & Dohme GmbH, a subsidiary of Merck & Co., Inc., is a pharmaceutical company based in Amt Neuhaus, Lower Saxony, Germany. Founded in 2001, the company specializes in the research, development, and manufacturing of medications and vaccines. MSD is particularly focused on oncology, where it develops innovative treatments aimed at improving survival rates and quality of life for cancer patients. The company also addresses infectious diseases and has a robust pipeline of products in various stages of clinical research. MSD is dedicated to enhancing global health outcomes by making its medications and vaccines accessible to healthcare providers and patients alike. With a workforce of approximately 2,438 employees, MSD is one of the prominent pharmaceutical manufacturers in Germany, contributing significantly to the healthcare landscape.


25. Eisai Co., Ltd.


Eisai Co., Ltd., founded in 1941 and based in Bunkyo City, Tokyo, Japan, is a pharmaceutical company that specializes in drug discovery and development. The company is particularly focused on oncology and neurology, striving to create innovative treatments that enhance patient outcomes. Eisai's research and development efforts are extensive, with a significant pipeline dedicated to oncology, showcasing their commitment to addressing cancer-related health challenges. They serve healthcare providers and organizations, emphasizing access to medicines and improving patient care. With a workforce of over 600 employees and operations in multiple countries, including Japan, the United States, and Vietnam, Eisai is positioned as a significant player in the pharmaceutical industry, particularly in the oncology sector.


26. Lead Pharma

  • Website: leadpharma.com
  • Ownership type: Corporate
  • Headquarters: Oss, North Brabant, Netherlands
  • Employee distribution: Netherlands 100%
  • Latest funding: November 2023
  • Founded year: 2007
  • Headcount: 11-50
  • LinkedIn: lead-pharma

Lead Pharma, founded in 2007 and based in Oss, North Brabant, Netherlands, is a clinical-stage pharmaceutical company that specializes in the discovery and development of innovative small-molecule therapies. The company emerged as a spinoff from the Hubrecht Institute and the University Medical Center Utrecht, leveraging academic expertise to address critical health challenges. Lead Pharma's focus is on creating effective treatments for patients with unmet medical needs, particularly in the fields of cancer and autoimmune diseases. Their research and development pipeline includes several promising projects targeting key biological processes in cancer, such as the RORγt, ERRα, and PRMT5 pathways. The company operates from Pivot Park, a biopharmaceutical life sciences campus, and collaborates with specialized contract research organizations to enhance their drug discovery capabilities. With a dedicated team of professionals, Lead Pharma aims to develop life-changing therapies that can significantly improve patient outcomes.



Cancer Drug Manufacturing Insights: Key Companies


CompanyHeadquarterSizeFoundedOwnership
TherDose Pharma Private LimitedHyderabad, Telangana, India201-5002003Private
Chi-Med (Hutchison China MediTech)Hong Kong S.A.R5001-100002000Private
Taiho Oncology, Inc.United States (USA)201-5002002Private
Haihe BiopharmaShanghai, Shanghai, China51-2002011Private Equity
Beta Pharma, Inc.United States (USA)11-501996Private
Sobhan Oncology PharmaceuticalRasht, Gilan, Iran51-2002002Private
Radiomedix, Inc.Houston, Texas, United States (USA)11-502006Private Equity
Ciro Pharma Private LimitedHyderabad, Telangana, India201-5002022Private
Florencia HealthCareNoida, Uttar Pradesh, India11-502011Private
Getwell OncologyGurugram, Haryana, India51-2001985Family Owned
Eurolab (Pty) Ltd.Sandton, Gauteng, South Africa11-502011Private
Innokeys Pte LtdSingapore11-502012Private
ImmuneOncia Therapeutics Inc.Gangseo-Gu, Seoul, South Korea11-502016Venture Capital
Sudair Pharmaceutical CompanyRiyadh, Riyadh, Saudi Arabia51-2002014Corporate
DendreonSeal Beach, California, United States (USA)501-10001992Corporate
Nano DaruTehran, Tehran, Iran201-5002011Private
1200 PharmaCulver City, California, United States (USA)11-502017Venture Capital
Kite PharmaSanta Monica, California, United States (USA)1001-50002009Corporate
Anaveon AgBasel, Basel, Switzerland11-502017Venture Capital
Xuanzhu Biopharmaceutical Co., Ltd.Shijiazhuang, Hebei, China201-5002002Private
PeptomycBarcelona, Catalonia, Spain11-502014Venture Capital
Pinnacle Life Science Pvt. Ltd (Subsidiary of Aarti Drugs)Mumbai, Maharashtra, India1001-50002014Private
Tallac TherapeuticsBurlingame, California, United States (USA)11-502018Venture Capital
MSD Sharp & Dohme GmbHAmt Neuhaus, Lower Saxony, Germany1001-50002001Private
Eisai Co., Ltd.Bunkyo City, Tokyo, Japan1001-50001941Private
Lead PharmaOss, North Brabant, Netherlands11-502007Corporate


Want to Find More Cancer Drug Manufacturing Companies?

If you want to find more companies that develop advanced oncology therapies and treatments for patients you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

  • Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
  • Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
  • Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!